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Introduction
Lung cancer remains to be the leading cause of cancer death in the United States 
with over 154,000 lung cancer deaths estimated in 2018 [1 https://www.cancer.org/
cancer/non-small-cell-lung-cancer/about/key-statistics.html]. Proton beam therapy 
(PBT) has been increasingly used for lung cancer, mainly because of its dose advantage 
over conventional radiation therapy such as 3D conformal radiation therapy (3DCRT) 
and intensity modulated radiation therapy (IMRT), and the increased number of 
proton therapy centers becoming available. Based on how a proton beam is spread 
out laterally and in depth, there are three main types of proton delivery techniques: 
passive scattering proton therapy (PSPT), uniform scanning proton therapy (USPT), 
and pencil beam scanning (PBS) [1-3]. 
Abstract
Purpose: Adaptive planning is often needed in lung cancer proton therapy to account for geometrical 
variations, such as tumor shrinkage and other anatomical changes. The purpose of this study is to 
present our fi ndings in adaptive radiotherapy for lung cancer using uniform scanning proton beams, 
including clinical workfl ow, adaptation strategies and considerations, and toxicities. 
Methods: We analyzed 165 lung patients treated using uniform scanning proton beams at our 
center. Quality assurance (QA) plans were generated after repeated computerized tomography (CT) 
scan to evaluate anatomic and dosimetric change during the course of treatment. Plan adaptation was 
determined mutually by physicists and physicians after QA plan evaluation, based on several clinical and 
practical considerations including potential clinical benefi t and associated cost in plan adaption. Detailed 
analysis was performed for all patients with a plan adaptation, including the type of anatomy change, 
at which fraction the adaption was made, and the strategy for adaptation. Toxicities were compared 
between patients with and without plan adaptation. 
Results: In total, 32 adaptive plans were made for 31 patients out of 165 patients, with one patient 
undergoing adaptive planning twice. Anatomy changes leading to plan adaptation included tumor 
shrinkage (17), pleural effusion (3), patient weight loss (2), and tumor growth or other anatomy change 
(9). The plan adaptation occurred at the 15th fraction on average and ranged from the 1st to 31st fraction. 
Strategies of plan adaptation included range change only (18), re-planning with new patient-specifi c 
hardware (9), and others (5). Most toxicities were Grade 1 or 2, with dermatitis the highest toxicity rate. 
Conclusions: Adaptive planning is necessary in proton therapy to account for anatomy change and 
its effect on proton penetration depth during the course of treatment. It is important to take practical 
considerations into account and fully understand the limitations of plan adaptation process and tools 
to make wise decision on adaptive planning. USPT is a safe treatment for lung cancer patients with no 
Grade 4 toxicity.
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Previous studies have shown that compared to 3D conformal or intensity modulated 
photon radiation, proton beams can better spare the lung, esophagus, heart, cord, 
and other normal tissues while delivering the same or higher dose to the treatment 
target, potentially leading to better tumor control and less toxicity [4-12]. Using PSPT, 
Chang et al. reported that the dose to normal tissues and the integral dose to patients 
with non-small cell lung cancer (NSCLC) were signi icantly reduced compared to 3D-
CRT and IMRT [11]. Kadoya et al., reported that PSPT signi icantly reduced lung dose 
compared to stereotactic body radiation therapy (SBRT) for Stage I non-small-cell lung 
cancer [10]. For SBRT with a prescribed dose for 66 Gy, the mean dose, V5, V10, V15, 
and V20 were 7.8 Gy, 32%, 21.8%, 15.3%, and 11.4% for SBRT, but reduced to 4.6 Gy, 
13.2%, 11.4%, 10.1%, and 9.1% for proton therapy, respectively. In addition to less 
dose to the lung, Hoppe et al. reported that PSPT delivered less dose (D0.1cc and D5cc) 
to the heart, esophagus and bronchus compared to SBRT [9]. For locally advanced Stage 
III NSCLC patients, Wu et al. found that proton beam therapy was feasible and would 
spare lungs, heart and spinal cord better compared to 3DCRT[5]. Because of its less 
proximal dose and better optimization capability, IMPT can further reduce doses to 
normal tissues, such as the lung, spinal cord, heart, and esophagus, compared to PSPT 
and IMRT for extensive Stage IIIB NSCLC, as reported by Zhang et al. [13]. Stuschke et 
al., also reported that IMPT was advantageous in terms of lung sparing compared to 
both Tomotherapy and IMRT [7]. The dosimetry of USPT for lung cancer was similar to 
PSPT, as reported by Zheng [14]. 
While proton beams provide a superior dose distribution due to their inite ranges, 
the dose advantage can be compromised due to range uncertainties and changes from 
the daily setup variation and anatomical change. This is of particular concern for lung 
cancer therapy since progressive anatomical changes such as tumor shrinkage and 
positional changes are often observed (Toward Adaptive, 1st paragraph). Hui et al., 
found that inter-fractional motion and anatomic change could lead to a result of up to 
8% reduction of CTV coverage and a mean 4.4 CGE maximum dose increase of spinal 
cord [20]. Koey et al., reported that without adaptive planning, target coverage could 
be dropped to below 60% for some lung cancer case undergoing proton therapy [21]. 
To account for the dose disturbance due to the anatomical changes, adaptive planning 
is often required to ensure optimal target coverage and normal tissue sparing during 
the whole course of proton therapy.
Uniform scanning proton therapy (USPT) has been used at our proton center for 
lung cancer patient treatment. Its use in adaptive planning of lung cancer patients and 
its toxicities has been rarely reported. The purpose of this study is to illustrate our 
work low, strategies, and practical considerations in adaptive planning of lung cancers 
using USPT. In addition, the acute and late toxicities for lung cancer patients treated at 
our center were also analyzed. 
Materials and Methods
Treatment techniques
Simulation: Each patient was simulated using GE CT scanner (Lightspeed 16, 
Wisconsin) and an RPM system (Varian, Palt, CA) for motion monitoring. Patients 
typically lied supine, were immobilized with a vacuum bag, which was on top of an 
index ixed framing device (wing board), and had their arms up and hands holding the 
pegs on the wing board. The patient was scanned at 2.5 mm slice thickness. If contrast 
is used, one computerized tomography (CT) scan should be taken before the contrast 
is injected in addition to one after the injection. The CT data with intravenous contrast 
will be used primarily for target delineation, and the CT data set without contrast 
will be used for dose calculation. Tumor motion was evaluated by physics team. If the 
magnitude of motion was too big (e.g., larger than 1 cm), either motion management 
would be applied, such as the use of compression belt, or conventional photon therapy 
would be used for treatment instead of proton therapy. 
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Treatment planning: Based on the 4D CT scan, the internal gross target volume (IGTV) 
was contoured on the maximum intensity pixel (MIP) images and expanded 7–10 mm 
to generate the clinical target volume (CTV). The CTV was further expanded by 5 mm 
to obtain the planning target volume (PTV). Treatment planning and dose calculation 
were performed on the average CT, using the XiO TPS (Version 5.0, Elekta Inc., St. Louis, 
MO). To account for the tissue density change in proton beam path at the presence of the 
tumor motion, IGTV was overridden to a proton stopping power ratio of tumor tissue, 
about 1.01 based on sampling of over 10 lung patients treated at our center. In addition, 
a smearing of 10 mm was used in compensator calculation for all lung cancer treatment 
planning. 2–4 ields were employed in a treatment plan. Target coverage and doses to 
normal tissues such as spinal cord, heart and lung, were evaluated to optimize the beam 
angle and beam weight for optimal dose distribution. Most patients were treated with 2 
CGE (Cobalt Gray equivalent) per fraction for a total dose of from 60 to 74 CGE. A small 
portion of patients were treated with hypo-fractionation, such as 10 CGE by 3 fractions, 
10 CGE by 4 fractions, and 12.5 CGE by 4 fractions. 
Treatment delivery. Each patient was treated using uniform scanning proton beams 
exclusively at our center. The proton therapy unit was made by IBA (Louvain-La-Neuve, 
Belgium). During the treatment, patients were set up using the same immobilization 
device as CT simulation and positioned as closely as possible to simulation. Orthogonal 
x-ray images were used to align and verify the patient positioning and setup every day 
before treatment. Proton beam was delivered layer by layer with the deepest layer 
delivered irst. The beam delivery time was typically 1 minute or less per beam, and the 
total patient in room time was about half hour or less for both setup and beam delivery. 
Adaptive planning
Adaptive treatment planning was performed to ensure optimal target coverage 
and normal tissue sparing when patient anatomy or tumor motion changed during 
the course of treatment for lung cancer patients. For each patient, repeated 4D CT 
scanning was performed after patients received about 14 CGE, 30 CGE, and 50 CGE. The 
new CT image set was registered to the initial CT data, using the VelocityAI software 
system (Version 3.1.0, Varian Medical Systems, Palo Alto, CA). Contours were copied 
from the initial CT to the new CT, and modi ied as needed. A quality assurance (QA) 
plan was then generated by applying the same proton beams in the original plan to 
the registered new CT dataset. Physicists and physicians would review the QA plan 
and determine whether plan adaptation was needed based on several clinical and 
practical considerations: the PTV coverage and normal tissue dose in the QA plan, the 
dose deviation from the original plan, the number of fractions remained, and the effort 
and cost to implement the adaptive plan (e.g., whether new hardware fabrication was 
involved). If plan change was determined necessary, plan adaptation was applied by 
either adjust proton ranges for certain beams, adjust beam weight, or replanning with 
the newly repeated 4D CT. The adapted plan would be used to treat the patient as soon 
as possible after necessary QA and hardware fabrication. The process of treatment, 
QA CT, QA planning, and plan adaptation will be repeated until the patient complete 
the treatment course. A clinical work low of the adaptive planning for lung cancer 
treatment at our center is shown in igure 1. 
Patients and toxicities
In total, we analyzed 165 patients that were treated at our proton therapy center. 
Among them, 62% of patients were male and 28% female. 14% of patients had small 
cell lung cancer, and 86% of patients had non-small cancer. The disease stage ranged 
from stage IA to stage IV. The patients ranged from 49 to 91 years old, with a mean age 
of 70.8 years old. 
The toxicity data was obtained from the research database that was maintained by 
the Proton Collaborative Group (PCG). Toxicity analysis was based on the 143 out of 
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165 patients who were enrolled in the PCG protocols. The patients undergoing adaptive 
planning were manually identi ied and their toxicity data was analyzed separately for 
comparison with patients without adaptive planning. 
Results
Adaptive planning
In total 32 adaptive plans (19%) were made, with one patient experiencing plan 
adaptation twice. The main reasons leading to plan adaptation include tumor shrinkage 
(17), tumor growth (6), pleural effusion (3), weight loss (2), and others (3). The plan 
adaptation strategies include range change only (18), range and modulation change 
(3), range, modulation, and weight change (2), and replanning (9) (Figure 2). 
 The time when a plan adaptation was made ranged from the 1st fraction to 31st 
fraction, with average of about 3 weeks from treatment start, i.e., at about the 17th 
fraction. The time from QA CT was scanned to the 1st treatment with the adaptive plan 
ranged from 1 to 2 days when no new hardware was needed, and 3-4 days when it was 
re-planned with new hardware, i.e., apertures and/or range compensators. 
Toxicities 
The toxicity rate for lung cancer patients with and without adaptive planning is 
shown in igure 3. Dermatitis is the most common toxicity for both patients with and 
without adaptive planning, followed by esophagitis, hoarseness and constipation for 
patient with adaptive planning, and fatigue, cough, esophagitis for patients without 
adaptive planning. The majority of toxicities are Grade 1 and Grade 2. Grade 3 
occurrence was very rare Grade 3 and no Grade 4 toxicity was found. 
a) b)
Figure 2: An example of plan adaptation by increasing proton range.  Patient developed fl uid buildup at the 25th fraction, 
leading to target under coverage for the QA plan (a). Proton range was increased by 2.2 cm in the adjusted plan (b).
Figure 1: A clinical workfl ow of adaptive planning for lung cancer treatment using uniform scanning proton therapy 
(from Zheng [15]).
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Discussion
In this study, we presented our indings on adaptive planning for lung cancer 
therapy using USPT, including clinical work low, practical considerations and 
toxicities. To our knowledge, the study is the irst to report such indings on adaptive 
lung cancer treatment using USPT. About 19% of patients in this study underwent 
adaptive planning using USPT, which is similar to what was reported using other 
proton therapy techniques. For lung cancer treatment with PSPT, Koay et al. reported 
that 20.5% of lung cancer patients underwent adaptive planning [16]. For PBS or 
IMPT, Chang et al. reported that 26.5% patients were re-planed [17]. Please note that 
the strategy used for plan adaptation depends largely on the institutional practice and 
the beam delivery technique used for lung cancer treatment. Re-planning based on the 
new CT data is a straightforward way commonly used for adaptive treatment for both 
PSPT and PBS and can also be used for USPT. However, USPT delivers a homogeneous 
dose to target region, and the proton range can be easily adjusted, so we can adapt 
the plan by simply adjusting the proton range (and/or modulation width) to maintain 
similar dose coverage due to anatomy change for certain cases. 
The criteria on whether to adapt a plan can vary from institution to institution as 
well as the individual physicist or physician who reviews the QA plan. At our center, 
several factors were considered to decide a plan change: 1) whether the target dose 
coverage and normal tissue dose meet the dose constraints; 2) how much the changes 
are in target dose coverage and normal tissue dose between the QA plan and initial 
plan; 3) how many fractions are left; 4) how easily and how quickly to adapt a plan, 
e.g., whether it is a simple range/modulation change or a replan that needs new 
hardware fabrication; and 5) what the performance status and treatment goal of the 
patient and potential clinical impact for the patient are. While plan adaptation would 
typically improve dosimetric distribution of a treatment plan, it is also associated to 







Figure 3: Toxicity rate for lung cancer patients treated with USPT. a) with adaptive planning. b) without adaptive 
planning.
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and potential treatment errors and safety concern associated with any plan change. 
Therefore, it is our recommendation to consider other clinical and practical factors 
in addition to DVH endpoints when we decide on whether to make a plan adaptation. 
It is critical to fully understand the limitations in plan adaptation process and 
software tools when evaluating a QA plan. The patient setup in QA CT could be different 
from the initial CT scan, the image registration software may be not accurate, and the 
QA plan generation may be incorrect. For example, our treatment plan system does 
not account for the patient pitch and roll when a QA plan is applied to the new CT 
data. Also, the beam isocenter for the QA plan was manually placed by a dosimetrist 
based on image registration, which could be incorrectly placed, especially when 
different isocenters were used for an initial and boost plan. These limitations or errors 
in the image registration and QA plan process could result in arti icial dose deviation 
unrelated to anatomy change, leading to unnecessary or incorrect plan adaptation. 
Therefore, our practice is to always analyze the anatomy change and the correlation 
between the dose change and anatomy change when we evaluate the QA plan and its 
dose distribution. If noticeable dose change is in the QA plan but not correlated patient 
anatomy/motion change or setup variation, it is likely that the dose change is arti icial 
as a result of software limitations or human errors, and further investigation should 
be warranted.
The top three toxicities for lung cancer therapy using USPT are dermatitis, 
esophagus, and fatigue, and no Grade 4 toxicity was found in our study. These indings 
are similar to those for patients treated using PSPT [16,18]. Pneumonitis was rare 
among the patients in the study; however, it was not entered in the PCG database, 
therefore not included in our toxicity analysis. Overall, we believe USPT is an effective 
and safe treatment for lung cancer patients. 
Currently, of line adaption has been used at our center and most other proton centers, 
mainly because of lack of in room CT imaging, the long turnaround of manufacturing 
patient speci ic device such as apertures and compensators, and lack of better tools 
on QA plan generation and dose accumulation. However, pencil beam scanning has 
been a mainstream in newly constructed proton centers, in room cone beam CT or 
CT on rails are becoming available [12,15,19], and better tools are being developed 
in image registration, dose accumulation, and plan adaptation. These advancements 
would make online adaptation for proton therapy possible in the future. 
Conclusion
In conclusion, USPT is a safe treatment for lung cancer patients. Adaptive planning 
is necessary in proton therapy to account for anatomy change and its effect on proton 
penetration depth during the course of treatment. It is important to take practical 
considerations into account and fully understand the limitations of plan adaptation 
process and tools to make wise decision on adaptive planning.
References
1. DeLaney TF, Kooy HM. Proton and Charged Particle Radiotherapy. 2015: Wolters Kluwer Health. 
2.  Paganetti H. Proton Therapy Physics. 2011: Taylor & Francis. Ref.: https://goo.gl/dSHSA5 
3. Zheng Y, Ramirez E, Mascia A, Ding X, Okoth B, et al. Commissioning of output factors for uniform 
scanning proton beams. Med Phys. 2011; 38: 2299-2306. Ref.: https://goo.gl/5A11nN 
4. Cushman TR, Verma V, Rwigema JM. Comparison of proton therapy and intensity modulated photon 
radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design. 
J Thorac Dis. 2018; 10(Suppl 9): S988-S990. Ref.: https://goo.gl/hDJ5cw 
5. Wu CT, Motegi A, Motegi K, Hotta K, Kohno R, et al. Dosimetric comparison between proton beam 
therapy and photon radiation therapy for locally advanced non-small cell lung cancer. Jpn J Clin 
Oncol. 2016; Ref.: https://goo.gl/zRAoAi 
Adaptive planning and toxicities of uniform scanning proton therapy for lung Cancer patients
Published: September 13, 2018 061
6. Ohno T, Oshiro Y, Mizumoto M, Numajiri H, Ishikawa H, et al. Comparison of dose-volume histograms 
between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung 
cancer. J Radiat Res. 2015; 56: 128-133. Ref.: https://goo.gl/ZAEV5J 
7. Stuschke M, Kaiser A, Pöttgen C, Lübcke W, Farr J. Potentials of robust intensity modulated scanning 
proton plans for locally advanced lung cancer in comparison to intensity modulated photon plans. 
Radiother Oncol. 2012; 104: 45-51. Ref.: https://goo.gl/vR3bxv 
8. Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small cell lung cancer 
patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with 
photon plans highlights importance of range uncertainty. Int J Radiat Oncol Biol Phys. 2012; 83: 354-
361. Ref.: https://goo.gl/9qDbxL 
9. Hoppe BS, Huh S, Flampouri S, Nichols RC, Oliver KR, et al. Double-scattered proton-based stereotactic 
body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic 
body radiotherapy. Radiother Oncol. 2010; 97: 425-430. Ref.: https://goo.gl/fC33ym 
10. Kadoya N, Obata Y, Kato T, Kagiya M, Nakamura T, et al. Dose-volume comparison of proton 
radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol 
Biol Phys. 2011; 79: 1225-1231. Ref.: https://goo.gl/PfccUY 
11. Chang JY, Zhang X, Wang X, Kang Y, Riley B. et al. Signifi cant reduction of normal tissue dose by 
proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation 
therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1087-
1096. Ref.: https://goo.gl/CFxHxe 
12. Veiga C, Janssens G, Teng CL, Baudier T, Hotoiu L, et al. First Clinical Investigation of Cone Beam 
Computed Tomography and Deformable Registration for Adaptive Proton Therapy for Lung Cancer. 
Int J Radiat Oncol Biol Phys. 2016; 95: 549-559. Ref.: https://goo.gl/EoS9hd 
13. Zhang X1, Li Y, Pan X, Xiaoqiang L, Mohan R, et al. Intensity-modulated proton therapy reduces the 
dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering 
proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-
cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010; 77: 357-366. Ref.: 
https://goo.gl/iDdbVs 
14. Zheng Y. Adaptive Radiotherapy for Lung Cancer Using Uniform Scanning Proton Beams, in 
Radiotherapy, C. Onal, Editor. 2017; IntechOpen. Ref.: https://goo.gl/kbSt3v 
15. Zhang M, Zou W, Teo BK. Image guidance in proton therapy for lung cancer. Transl Lung Cancer Res. 
2018; 7: 160-170. Ref.: https://goo.gl/vSfn6B 
16. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, et al. Adaptive/nonadaptive proton radiation planning 
and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol 
Biol Phys. 2012; 84: 1093-1000. Ref.: https://goo.gl/bqi4TP 
17. Chang JY, Li H, Zhu XR, Liao Z, Zhao L, et al. Clinical implementation of intensity modulated proton therapy 
for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014; 90: 809-818. Ref.: https://goo.gl/sQLNjc 
18. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, et al. Toxicity and patterns of failure of adaptive/
ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat 
Oncol Biol Phys. 2011; 80: 1350-1357. Ref.: https://goo.gl/cjm9G4 
19. Hua C, Yao W, Kidani T, Tomida K, Ozawa S, et al. A robotic C-arm cone beam CT system for image-guided 
proton therapy: design and performance. Br J Radiol. 2017. 90: 20170266. Ref.: https://goo.gl/XvBRjZ 
